Management of DAAs Failure

03.03.2017 • Views

Share Embed Flag

Management of DAAs Failure

If you have failure of plan A in treating a patient with chronic hepatitis C. What's your plan B

DOWNLOAD ePAPER

ialwaysforget123

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

START NOW

Post-treatment RAV(S) persistence in patients who failed<br />

to achieve SVR

2
3
4
5
6
7
8
9
10
11
13
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31

PROGRAM SIMPLIFIED

GIT stents, round table interactive session EDDW March, 29

March, 29 round-table discussion: Meet the Expert at GIT Sent Session

Program of Round-table Session: GIT Stents

HCC: what s new?

What’s New in Hepatology?

Hepatitis E: What’s New?

Where are we on the path to eliminate hepatitis C virus ?

Management of HCV G4 Kasr Alainy

Stents in GIT

Stents in GIT

Preliminary Workshop Cases, Feb. 22nd

Kasr El-Aini Final Program

FINAL PROGRAM KASR AL AINI GIT/HEPATOLOGY/ENDOSCOPY

Post-treatment RAV(S) persistence in patients who failed to achieve SVR

Page 2 and 3: Management of DAAs Failure Prof. Ga
Page 4 and 5: • HCV is an enveloped, positive-s
Page 6 and 7: Antiviral Resistance • Each patie
Page 8 and 9: All DAAs Can Select Resistant Varia
Page 10 and 11: Barrier to Resistance Low-barrier d
Page 13: NS5B RAV(S) • Sofosbuvir has a hi
Page 17 and 18: Pts With NS5A RAVs (%) Durability o
Page 19 and 20: Guidelines of the National Treatmen
Page 21 and 22: Treatment recommendations for retre
Page 23 and 24: Treatment recommendations for retre
Page 25 and 26: A- Retreatment of patients with pre
Page 27 and 28: Future Therapy of HCV With the help
Page 29 and 30: AASLD 2016 Sofosbuvir/Velpatasvir/V
Page 31: THANK YOU please visit www.gamalesm